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Abstract 
The administration of drugs through the pulmonary route offers great advantages, 
but also requires overcoming many challenges. There is a need to develop appropriate 
carriers for each active molecule to be delivered to the desired site in the lung, either for a 
local or a systemic effect. The polysaccharide chitosan is a very promising material for this 
purpose, given its demonstrated properties of biodegradability and biocompatibility, as 
well as mucoadhesivity and ability to enhance macromolecules permeation. In this review, 
the potential of chitosan to develop drug carriers for delivery to the lung will be discussed. 
The most important features that can support its selection will be explained. Besides, 
different approaches to increase its performance, especially concerning solubility, 
permeation-enhancing properties and gene transfection efficiency, will be presented. 
Special emphasis will be placed on information of different chitosan-based carriers, 
namely nanoparticles and microparticles, intended for pulmonary drug delivery. 
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1. Introduction 
The field of drug delivery has been assisting recently to a strong biotechnological 
revolution, which brings new potential therapeutic molecules and macromolecules every 
day. However, the application of these substances in therapeutics requires overcoming 
many challenges related with the effective maintenance of their stability, circumvention of 
enzymatic degradation and diminution of immune reactions. In this manner, new strategies 
have arisen concerning their delivery to specific sites of action and both the design of 
adequate drug delivery systems and the definition of appropriate routes of administration 
have become critical features. Particularly, the pulmonary route offers great advantages for 
the administration of drugs, such as large surface area available for absorption in the 
alveoli, very thin diffusion path to the blood stream, extensive vascularisation, relatively 
low metabolic activity compared to other routes and avoidance of first pass hepatic 
metabolism (1,2). Anyhow, there is still the need to develop appropriate carriers for each 
active molecule to be delivered to the desired lung site, either for a local or a systemic 
effect. In fact, in order to succeed in the pulmonary delivery of any therapeutic molecule, 
many obstacles and lung defence mechanisms, which could hinder the path of foreign 
substances, must be overcome, such as the effect of the airways’ structure, the mucociliary 
clearance and the phagocytosis by the alveolar macrophages (2,3) and, therefore, the 
applied carrier should comply with specific characteristics. In this manner, if a systemic 
effect is expected, the drug should reach the alveolar region, where systemic absorption 
mostly takes place; while in the case of a local action, the drug should arrive at the specific 
site of action, which could be for instance the bronchial region in the case of asthma 
therapy or again the alveoli in the case of tuberculosis (4). Considering the specific 
anatomy of the airways, it is traditionally believed that droplets and/or particles with 
aerodynamic diameter within the range of 1 – 3 μm will present appreciable deposition in 
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the alveolar region, while those with higher aerodynamic diameter will be mainly 
deposited in the tracheobronchial area (1). Therefore, it becomes obvious that size and 
density of the delivery systems will both play a critical role in obtaining adequate 
therapeutic effect.  
The selection of suitable drug carriers is a crucial factor to succeed in lung delivery 
and, hence, materials (polymers, lipids, sugars) used for their preparation are an essential 
parameter to consider. Amongst the polymers that have been proposed as valuable 
alternatives for this purpose, polyesters, acrylates, cellulose derivatives and 
polysaccharides have been mentioned in many occasions (5-7). Amid these polymers, 
chitosan, a natural polysaccharide derived from chitin, has been presented as a very 
promising excipient, given its demonstrated properties of biodegradability and 
biocompatibility (8), as well as mucoadhesivity and enhancement of macromolecules 
permeation, which facilitate its application in the development of mucosal drug delivery 
systems (9,10).  
In this review, the potential of chitosan as suitable excipient to develop drug 
carriers for delivery to the lung will be discussed. The most important features that can 
support its selection will be explained, while different approaches to increase its 
performance, especially concerning solubility, permeation-enhancing properties and gene 
transfection efficiency, will be presented. Special emphasis will be placed on information 
of different chitosan-based carriers, namely nanoparticles and microparticles, intended for 
pulmonary drug delivery. In this manner, indications on the in vitro as well as in vivo 
studies will be provided, and methods applied for their production will also be addressed. 
 
2. Chitosan: a naturally occurring polymer 
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Chitosan [α-(1-4)-2-amino-2-deoxy-β-D-glucan] is a cationic polysaccharide which 
is composed of repeating units of N-acetylglucosamine and D-glucosamine (Figure 1). 
Being the second most abundant polysaccharide in nature, only preceded by cellulose (11), 
it is obtained by the deacetylation of chitin, the main component of crustaceans 
exoskeleton and insects and, more recently, it has been obtained by biotechnological 
processes (12,13). The β-(1-4) glycosidic bonds linking the glucosamine units of chitosan 
can be destroyed by lysosyme, an enzyme that exists in all the mucosal surfaces of the 
organism, including the pulmonary (14).  
Chitosan possesses structural characteristics similar to those displayed by 
glycosaminoglycans (GAGs), which are an important component of connective tissues. 
Owing to that feature, it has been investigated for rather different biomedical applications, 
such as wound-healing, tissue engineering, dentistry and orthopaedics (13). Furthermore, 
chitosan presents the ability to attach to fat, preventing its absorption and, thus, is included 
in marketed dietary supplements, because it can induce weight loss (15). 
As it has been previously mentioned, chitosan presents well-documented favourable 
biological properties such as biocompatibility, biodegradability and low toxicity (8,16), 
which render this molecule very attractive for drug delivery. Moreover, increased attention 
has been paid to this polymer because of its reported mucoadhesive properties (9) and the 
ability to promote the permeation of macromolecules through well-organised epithelia 
(nasal, intestinal, ocular, buccal, pulmonary) (17-24), features which will be described in 
detail in a specific section of this review (section 4). 
Bearing in mind that this review focuses on the application of chitosan in drug 
delivery to the lung, its physicochemical properties, which might affect this specific use, 
will be addressed in the present section. Chitosan comprises a series of polymers with 
different molecular weight and percentage of acetyl groups and, hence, degree of 
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acetylation, characteristics which have been proving determinant in its behaviour (11). 
Actually, the main difference between chitin and chitosan is the number of acetyl groups, 
although this small difference turns to important features in their physicochemical 
properties, such as solubility (chitin is insoluble in water and in the most common organic 
solvents and, hence, not useful for pharmaceutical purposes, whereas chitosan is soluble in 
acidic solutions), biodegradability and mucoadhesivity (23). Displaying a pKa of 
approximately 6.5, in neutral or basic pH, chitosan is insoluble in water, while in acidic pH 
it becomes water-soluble, due to the protonation of most amino functions (13). Although it 
has been sometimes claimed that this behaviour strongly interferes with the biomedical 
application of the polymer, because it is insoluble at physiological pH (7.4), it also has 
been proven many times that chitosan-based formulations improved the therapeutic effect 
of macromolecules associated to the formulations, upon in vivo administration through 
physiological routes (19,21). This demonstrates that the presence of chitosan in the site of 
action as a dissolved form is not a critical issue to improve the therapeutic action of the 
carried molecules, although it might be decisive in the preparation of formulations. The 
degree of deacetylation of chitosan is a characteristic that affects its solubility (25), highly 
deacetylated chitosans (85%) being readily soluble in solutions with pH up to 6.5. It also 
plays a prominent role in its mucoadhesion properties. In this respect, highly deacetylated 
chitosans display increased mucoadhesivity, due to the presence of more positively 
charged amino groups available to mediate the interaction with the negatively charged 
mucus components (23). This explains that most scientific research reporting the 
pharmaceutical application of chitosan is performed with highly deacetylated chitosans. 
Apart from pH, ionic strength interferes with chitosan solubility too and, in this respect, 
higher ionic strength corresponds to lower solubility (23). 
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Chitosans administered as solutions by the pulmonary route are actually expected to 
precipitate, since the pH of the airway surface liquid is known to be approximately 7 (26). 
This has justified the proposal of a number of optimised chitosan presentations; either in 
the form of devices (nanoparticles, microparticles), which display better stability 
themselves and also provide increased stability to the carried therapeutic molecule, or as 
chitosan molecular derivatives, developed in order to achieve enhanced properties related 
to absorption promotion, transfection efficiency and better solubility at lung pH. These 
alternatives will be addressed in subsequent sections of this review.  
 
3. Chitosan derivatives: an approach to increase the potential for drug 
delivery  
Despite all the useful and promising properties displayed by chitosan, in certain 
applications it sometimes presents a few limitations related, for instance, to its solubility. 
As mentioned before, due to a pKa around 6.5, chitosan is insoluble in water, although it is 
soluble in acidic solutions (13). Over the recent years, this limitation has led to the 
development of several chitosan derivatives which are water-soluble over a wider pH 
range, including physiological pH. These chemically-modified chitosans include, among 
others, N-trimethyl chitosan (27) and N-carboxymethyl chitosan (28), which present, 
respectively, trimethyl and carboxymethyl groups bonded to the amino function, and, less 
commonly, N-succinyl chitosan (29) and thiolated chitosan (30), displaying, respectively, 
succinyl and thiol groups attached to the chitosan amino groups. Many other derivatives 
have been developed in order to specifically improve chitosan performance in applications 
such as gene delivery, achieved by hydrophilic, hydrophobic, pH-sensitive, temperature-
sensitive and specific ligand modifications (31). Hydrophilic modifications of the polymer, 
which include grafting of dextran, polyethylenglycol (PEG) or polyvinylpyrrolidone (PVP) 
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to chitosan, have rendered increased stability and longer circulation time to chitosan/DNA 
complexes due to the prevention of aggregation. Hydrophobic derivatives produced by 
binding N-dodecyl, deoxycholic acid, alkyl groups and stearic acid to the polymer or 
binding 5-cholanic acid to glycol chitosan, have demonstrated to increase transfection 
efficiency, while N-dodecylated chitosan also improved the thermal stability of DNA (31). 
Urocanic acid-modified chitosan (32), chitosan-graft-polyethyleneimine and polypropyl 
acrylic acid-modified chitosan have all been described as approaches for pH-sensitive 
chitosan modification to enhance its transfection efficiency (31). Increased transfection 
efficiency was also achieved by coupling chitosan to a carboxyl-terminated N-
isopropylacrylamide/vinyl laurate, derived from N-isopropylacrylamide which is a well 
known temperature-sensitive polymer (33). Finally, the same effect on transfection was 
described as a result of the interaction of chitosan with surfaces through specific ligands 
which were previously immobilised on the molecule, such as galactose, transferrin, folate 
and mannose, which interact with specific cell receptors (33).  
In spite of the great number of chitosan derivatives described in the literature, only 
a few have been reported specifically in the field of pulmonary delivery and, along this 
section, we will focus on the properties of those derivatives reported to this end. The 
narrow list of applications might be explained by the fact that most chitosan derivatives 
have not been subject to extensive study with regard to their benefits and limitations in 
drug delivery so far and, possibly, it will be a matter of time until works with other 
derivatives for lung administration application become available. 
N-trimethyl chitosan is a partially quarternised derivative of chitosan, prepared by 
reductive methylation of chitosan with methyl iodide in a strong basic environment at high 
temperature (27). This chitosan derivative provides higher water solubility over a broader 
pH range (11,27), since it presents trimethylated amino groups, the degree of methylation 
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depending on the reaction time and number of reaction steps (34). Moreover, it displays 
mucoadhesive character, as does the parent molecule, but a study demonstrated that it has 
lower intrinsic mucoadhesivity than chitosan hydrochloride or glutamate, due to 
conformational changes, which affect interpenetration in the mucus layer (35). Polyplexes 
(complexes of polymers with DNA), elaborated with this modified chitosan, have further 
proven to enhance gene transfection efficiency in A549 cells, an alveolar epithelial cell 
line, although inducing an increase in cytotoxicity, which can be overcome by using 
polyethyleneglycol-graft-trimethyl chitosan block copolymers (36). A hydrophobic 
derivative obtained by coupling stearic acid with a chitosan oligosaccharide, synthesised 
by an 1-ethyl-3-(3-simethylaminopropyl) carbodiimide-mediated coupling reaction, has 
also demonstrated ability to increase transfection efficiency in the same alveolar cell line, 
as a result of improved capacity for endosomal escaping. Moreover, in aqueous solution, 
this derivative forms micelle-like structures by self-aggregation and is used to form 
micelle/DNA complexes nanoparticles, which protect DNA from enzymatic degradation 
(37).  
Trisaccharide-substituted chitosan oligomers were obtained by substituting the 
oligomers with the trisaccharide branch at their primary amines. Polyplexes formed with 
this derivative have shown increased transfection efficiency both in vitro, in the bronchial 
epithelial cell line 16HBE14o-, and in vivo upon lung administration to rats. This effect 
was attributed to the targeting of this derivative to cell-surface lectins (38).  
Urocanic acid-modified chitosan is obtained by coupling water soluble chitosan 
with urocanic acid, via an active ester intermediate. Urocanic acid is composed of an 
imidazole ring and it binds to the chitosan amino groups through its carboxylic group (32, 
39). This chitosan conjugate provides enhanced transfection efficiency because the 
imidazole ring of urocanic acid plays an important role in endosomal rupture, a limiting 
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step for DNA delivery into the nucleus. It was reported that urocanic acid displays 
buffering capacity in the endosomal compartment, leading to the entrapment of positively 
charged ions by the amines of imidazole rings, which, consequently, enhances osmolarity 
and, subsequently, results in endosomal rupture and escape to cytoplasm (39). 
As can be easily understood, many efforts are being directed to the chemical 
modification of the original molecule of chitosan in order to obtain a polymer with 
enhanced properties. In fact, by means of chitosan modifications, its mucoadhesive 
properties can be enhanced, as can be improved its capacity to act as carrier for gene 
delivery, for instance, leading to improved results and better in vivo outcomes concerning 
therapeutic effect of the carried molecule.  
The most important objective of researchers is still to design appropriate vehicles 
for specific therapeutic molecules, enabling their intact release as close as possible to the 
site of action, provided their protection from harmful conditions. However, safety issues of 
the developed derivatives should be considered and the risk-benefit of their application, as 
compared to the original molecules, remains to be seriously evaluated. 
 
4. Benefits and limitations of chitosan for drug delivery to the lung  
As previously mentioned in this review, biotechnological advances are responsible 
for the development of a large number of therapeutic macromolecules, which pose many 
challenges related to their administration. Most of these molecules are hydrophilic and 
have high molecular weight as compared to conventional drugs, features that limit their 
permeation across biological barriers and render them suitable to degradation in the body 
fluids.  
Chitosan has been gaining increasing interest for the development of drug delivery 
systems that circumvent the limitations associated to the administration of these 
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macromolecules. In addition to the already cited biocompatibility, biodegradability and 
low toxicity of the polymer (8,16), which are all crucial in the design of drug carriers, 
chitosan also displays mucoadhesive properties (9) and the capacity to enhance absorption 
of macromolecules through mucosal barriers such as the nasal, intestinal, ocular, buccal 
and pulmonary (23). In fact, owing to its cationic character, chitosan is able to interact with 
the negatively charged sialic acid residues of membrane-bound glycoproteins, by means of 
electrostatic forces (40). Although this phenomenon takes place at the level of all the 
mucosal surfaces, this property is of particular importance in pulmonary administration, 
because it means that the administered drug delivery system will remain in the lung region 
until the turnover of the mucus layer, if it binds to the mucus layer, or it can even stay for a 
longer period of time, if it crosses the mucus layer and attaches to the epithelium cell 
membranes, thus attaining a prolonged drug effect. 
In a study performed by Grenha et al., upon in vitro incubation of fluorescein 
isothiocyanate bovine serum albumin (FITC-BSA)-loaded chitosan nanoparticles with 
Calu-3 and A549 cells, models of the bronchial and alveolar epithelia, respectively, it was 
demonstrated that the nanoparticles adhered to the cells surface, even after thorough 
washing, therefore evidencing the biodhesive properties of nanoparticles (41). 
One of the most prominent mechanisms of defence of the lung and, thus, one of the 
major concerns of scientists working in lung drug delivery, is the capture by alveolar 
macrophages, which has been reported to be strongly influenced by the particle size and 
material composition. However, as chitosan displays bioadhesion capacity, phagocytosis is 
delayed and this will, hence, allow the release of the carried therapeutic molecule (42). As 
easily understood from the mechanism of adhesion described above, the mucoadhesive 
character of chitosan will depend on its deacetylation degree. In this respect, a higher 
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deacetylation degree corresponds to the presence of more free amino groups and, thus, 
positive charges, which naturally enable greater adhesiveness (43). 
Although the lung route is recognised as providing macromolecules permeation, the 
mean relative bioavailability of macromolecules as compared to subcutaneous injection 
does not usually exceed 25%, maintaining the challenge of improving pharmacokinetics 
(2). In fact, several agents such as bacitracin (protease inhibitor), sodium taurocholate (bile 
salt) and unsaturated fatty acids of oleic acid, among others, have been proposed to 
promote the lung permeation of buserelin, insulin and calcitonin, respectively (44). 
However, the use of these substances has raised safety concerns regarding long-term 
effects, because some of them were demonstrated to induce irreversible alterations on the 
alveolar epithelial cell layer (45). Chitosan has been proving a valuable approach to solve 
this limitation. Due to its bioadhesive character, chitosan has the ability to adhere to mucus 
and cell membranes, therefore remaining concentrated in the area of absorption and 
allowing drug release in the lung over a prolonged period of time (40,46). Moreover, it has 
been shown that chitosan transiently opens cells’ tight junctions upon incubation with cell 
lines representative of the bronchial epithelium, such as Calu-3 and 16HBE14o- (47,48). 
This leads to a decrease of cells’ transepithelial electrical resistance (TER), which is 
mediated by the interaction of the positively charged amino groups of chitosan with the 
negatively charged sialic acid groups of membrane-bound glycoproteins (40). This 
reversible disruption of the tight junctions enables an increased permeation of the released 
macromolecule, and is dependent on several factors such as chitosan concentration, 
molecular weight and deacetylation degree (23). 
Chitosan has been described in the literature as biocompatible, biodegradable and 
non-toxic. However, few studies have focused on these subjects. In the same study in 
which a chitosan solution (pH 5.5) was found to induce a decrease of 30% in Calu-3 cell 
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viability upon 3h of incubation and to cause a strong inflammatory response (high levels of 
neutrophil infiltration in the lungs after in vivo administration), the 60% trimethylated 
chitosan derivative (TMC60) (pH 7.4) revealed mild or no effect in both cell viability and 
histological studies (48). In contrast, chitosan oligomer did not cause any membrane 
damage to lung tissue (as determined by leakage of lactate dehydrogenase in 
bronchoalveolar lavage) (49). According to Huang et al., chitosan (213 KDa, 88%) 
solutions and nanoparticles exhibit similar cytotoxicity (50). However, we have 
demonstrated that chitosan in the form of nanoparticles (prepared by ionic gelation 
technique) has short-term biocompatibility with the respiratory cells Calu-3 and A549, not 
inducing significant toxicity at concentrations as high as 1 mg/mL, for up to 48 h (41). 
The biological effects related to inflammation of rat lung upon contact with 
chitosan microparticles were examined (51), demonstrating that chitosan could induce 
proinflammatory responses in rat lung tissues in a dose-dependent manner, which is 
probably related to its cationic character. These effects were mild relative to those obtained 
with lipopolysaccharides and the doses tested were within the upper range of levels 
previously used in some therapeutic applications in which chitosan was used for 
pulmonary DNA delivery in mice (52). However, relatively higher doses of chitosan might 
be needed for delivery of other non-DNA therapeutic agents. Therefore, the main 
conclusion of this study is that these effects need to be considered in the context of 
therapeutic application via pulmonary delivery, especially if relatively high concentrations 
of chitosan are used.  
Furthermore, the type of chitosan chosen is of high importance, since the factors 
referred to greatly influence chitosan toxicity are the type of salt, the molecular weight and, 
mainly, the deacetylation degree. In this respect, a higher degree of deacetylation of 
chitosan, which represents a higher positive zeta potential of the particles, was related to a 
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higher in vitro cytotoxicity (50). Accordingly, in this context, the use of less deacetylated 
chitosan could be desirable. With this idea in mind, we have recently tested the Calu-3 
cells sensitivity to chitosans of different deacetylation degree (> 80%, 47% and 38%) in 
both proliferating and well-differentiated cells, observing significant differences. For 
instance, for a chitosan concentration of 1 mg/mL, cell viability in proliferating cells 
remained around 100% with respect to buffer control after 4 hours incubation, for both less 
deacetylated chitosans, whereas it was only 20% for the high deacetylated polymer. 
However, it must be mentioned that this marked difference was less pronounced in 
differentiated cells (41). 
Toxicity can be decreased by combining chitosan with other excipients suitable for 
lung delivery, like cyclodextrins. In fact, chitosan--cyclodextrin microspheres constitute a 
biocompatible and safe pulmonary carrier, taking into account that they do not produce 
neither hemolysis nor toxicity to rat implantation, apart from no genetic toxicity (53). 
In a comparative study, the lung toxicity of microspheres was compared to that of 
other materials by impinging the particles on Calu-3 monolayers and assessing the 
cytotoxicity, induction of cytokine release, changes in transepithelial permeability and 
electrical resistance. It was found that chitosan shows low toxicity, hence being 
particularly promising for systemic delivery in the lungs. Interestingly, one of the most 
commonly studied excipients for controlled release in the lungs, PLGA, has the highest 
toxicity of the polymers studied (54). 
Therefore, concerns still remain regarding chitosan long-term safety, as well as its 
clearance from the lungs, and future studies are required to elucidate the factors that may 
influence chitosan biocompatibility. Nevertheless, it should be reminded that lysozyme 
mediates the hydrolysis of chitosan into non-toxic amino sugars, which are, subsequently, 
processed by the organism (55). This enzyme is widespread in the lung, being secreted 10-
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20 mg/day (56), therefore ensuring the cleavage of chitosan units and enabling its 
elimination. 
 
5. Chitosan-based formulations for pulmonary drug delivery 
Recently, innovative delivery systems based on chitosan have been proposed for 
either local administration of i.e. anti-asthmatic drugs or systemic delivery of peptides and 
proteins, as well as for gene delivery (consult Table I). However, the application of the 
concepts of controlled and targeted delivery to the lungs is new and many concerns still 
remain regarding the safety and clearance of the polymeric carriers from the lungs.  
Furthermore, the successful administration of many drugs and macromolecules is 
seriously compromised by the lack of specificity of the drug carrier towards a given target 
and, consequently, a portion of the administered dose will not be localised at the target site 
but remain therapeutically unavailable, while increasing the occurrence of side effects. 
Although the pulmonary epithelium is highly permeable, there is still the need to design 
drug delivery systems which provide the protection of the active molecule from the lung 
defence mechanisms, thus enabling stronger therapeutic effects in vivo. 
Based on the previously commented advantages of chitosan for lung drug delivery, 
several chitosan-based liquid and powdered formulations (solutions, nanoparticles, 
microparticles) were developed, aimed at improving the lung performance of several 
macromolecules. Among them, the incorporation of drugs in polymeric particles, either 
nano- or micronsized, has been shown to provide effective delivery to the target site, while 
simultaneously preventing instability issues and, many times, enabling their controlled 
release, leading to an increased therapeutic benefit and reduction of side effects (45,57). 
The characterisation of these chitosan-based formulations in terms of their in vitro 
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performance, biocompatibility and pharmacological effect, will be addressed in this 
section. 
 
5.1. Chitosan solutions  
Chitosan solutions were rarely proposed as drug vehicles to the lung. A chitosan 
(93% deacetylation degree, MW 100-500 kDa) solution containing 190 μM of the peptide 
octreotide has proven to decrease the TER of Calu-3 cells in vitro about 50% and to 
enhance octreotide permeation by 21 fold, comparing to a control of the peptide in buffer. 
Upon its in vivo administration (0.97 mM) with the chitosan solution to rats, the protein 
bioavailability increased 2.4 fold comparing to the administration without chitosan and the 
authors described a linear in vitro/in vivo correlation (48). Since chitosan has a pKa around 
6.5, its stability is seriously compromised in media with pH above that value. The lung 
lining fluid is assumed to have a pH of approximately 7 (26) and, thus, it would not be 
surprising that chitosan precipitates upon contact with the lung environment. In order to 
circumvent this limitation, the chemical modification of chitosan is becoming common and 
N-trimethyl chitosan is one of the most used and studied chitosan derivatives (27), with 
free solubility at neutral and basic pH (please consult section 3 for a more detailed 
description). 
 TMC60 (60% trimethylated chitosan derivative) performs better than chitosan, 
reducing the cells TER by 65% and enhancing the permeation and in vivo bioavailability 
(30 fold and 3.9 fold, respectively) of the protein octreotide compared to the controls.  
Moreover, as it was previously indicated, TMC60 (pH 7.4) induced mild or no effects in 
both cell viability and histopathological studies (48).  
In this section, it is necessary to mention the use of chitosan oligomers, which are 
obtained from the parent molecule by hydrolysis and shows great potential for improving 
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the lung absorption of bioactive peptides. In fact, a solution of chitosan hexamer (985 Da) 
containing interferon- (IFN-) (2 × 107 IU/mL) has proven more effective in enhancing 
the pulmonary absorption of the peptide than the chitosan polymer (MW = 96 kDa), 
achieving a maximum serum concentration (Cmax) of 1006 IU/mL (hexamer) against 513 
IU/mL of the parent polymer. Moreover, IFN- relative bioavailability as compared to 
intramuscular injection was 17.8% for the hexamer and 8.5% for the original polymer. 
Furthermore, the oligomer did not cause any membrane damage to lung tissue, as 
determined by leakage of lactate dehydrogenase in bronchoalveolar lavage (49).  
Stability issues, either concerning shelf-life or administration, are a major drawback 
in formulating drugs in solutions. When administering a solution of a drug, it should be 
considered that the molecule itself, unless otherwise mentioned, is completely exposed to 
the action of the physiological conditions of the route of administration and, in this 
particular case, of the lung environment. Solutions do not usually provide any, protection 
of the molecule and do not allow for a controlled release. Therefore, other administration 
devices, such as microparticles and nanoparticles are gaining much popularity and have 
been proving over the last years that they are the more valuable candidates for the future of 
drug delivery. 
 
5.2. Chitosan microspheres 
The majority of the dry powder inhalation systems currently available consist in a 
micronized form of the active drug by itself or together with an excipient like lactose. 
However, recently, research work in this field has focused on the design and formulation of 
microspheres that can be tailored with the desired morphology (shape and porosity) and 
aerodynamic properties (size and density) for lung delivery (5). As it has been previously 
mentioned, these microspheres could be prepared using a wide range of synthetic and 
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naturally occurring polymers and materials and can offer efficient and controlled delivery, 
as well as protection of the encapsulated molecules. Microspheres produced from chitosan 
arise with a great potential as protein lung carriers. Besides, microspheres can allow the 
whole dose of loaded drug to reach the desired area, thus exhibiting increased therapeutic 
efficacy while reducing the number of needed doses and undesirable side effects. 
Traditionally, particles within 1 and 3 μm geometric diameter and density around 1 g/cm3 
were thought to be the most suitable for lung delivery, since significant loss due to impact 
and exhalation of large and small particles, respectively, were avoided (45). Later, in an 
attempt to overcome limitations of particle aggregation and rapid phagocytosis by alveolar 
macrophages, it was introduced a new and promising concept based on the design of large 
and light porous particles (58, 59), with a mass density of approximately 0.1 g/cm3 and 
geometric diameter of > 5 m, exhibiting an aerodynamic diameter which is smaller (< 5 
m) than their geometric diameter. Because of these features, particles can be aerosolized 
more efficiently, resulting in higher respirable fractions of the formulation, and can evade 
alveolar phagocytosis (60-62). Nevertheless, the fate of microspheres entering the lungs is 
dependent on the manufacturing material and technique and on the delivery device. Spray-
drying is a very valuable technique for producing dry powders suitable for pulmonary 
delivery of drugs (63). Spray-drying of compounds of different compositions resulted in a 
change of particle morphology  (64), which is of potential importance in the development 
of therapeutic powder aerosol formulation. The particle size of the obtained microparticles 
usually ranges from a few microns to several tens of microns and has a relatively narrow 
distribution. Recently, a number of articles have been published describing the preparation 
of chitosan microparticles intended for lung delivery by such spray-drying methods (58-62, 
65-71).  
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We have produced chitosan microspheres with different morphological 
characteristics and adequate aerodynamic properties (aerodynamic diameter less than 5 µm 
and tap densities as low as 0.23 ± 0.02 g/cm3) to reach and deposit in the deep lung 
(alveolar region), where the loaded protein is intended to be delivered and absorbed. 
Morphology and surface appearance of the chitosan microspheres as well as their densities 
and aerodynamic diameters were easily modulated by varying their composition (chitosan 
type and chitosan-glucomannan ratio) and polymer degree of deacetylation. These particles 
have a spherical shape and there is an evolution from the spherical shape to a convoluted 
surface as the chitosan deacetylation degree decreases or the content of the polysaccharide 
glucomannan increases. The application of this micron-sized system as lung protein carrier 
was investigated using insulin and fluorescein isothiocyanate-labelled bovine serum 
albumin (FITC-BSA) (protein association efficiencies of 90% - 100%) as model 
compounds. Preliminary in vivo results of the insulin-loaded microspheres are very 
encouraging, demonstrating that they induce a significant decrease and prolonged 
reduction of glucose levels (5). Our hypothesis was that, once in the absorption site, 
chitosan would improve pulmonary protein absorption by interacting with the epithelial 
cells, as had been previously reported for chitosan nanoparticles (19,20,22). Interestingly, 
crosslinked chitosan microspheres have been shown to be compatible with the 
hydrofluoralkane propellant P134a and, therefore, they are good candidates for lung 
delivery via pressurized metered dose inhalers (pMDI) (65).  
However, when aerosolized alone, the forces generated within the dry powders can 
be insufficient to entrain the microparticles as a result of poor flowability and particle 
aggregation. Entrainment can be aided by the addition of a coarse carrier, such as lactose 
or mannitol (66). In addition to powder entrainment, one of the key factors that determine 
the fine particle faction is the ability of the inhaler to produce forces sufficient to 
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deagglomerate the microparticles from the coarse carrier. Therefore, Sivadas et al. 
produced by spray-drying similar FITC-BSA-loaded chitosan microparticles, with a 
geometric diameter of 5.49 m, theoretical mass mean aerodynamic diameter of 2.91 m, 
density of 0.28 g/cm3 and with an encapsulation efficiency of 59.2%. Then, these 
microparticles were mixed with mannitol at a ratio of 24:1 (mannitol:microparticles) and 
the mannitol-blended microparticles were aerosolized through a multi-dose dry powder 
inhaler (DPI) using a multi-stage cascade impactor (Andersen cascade impactor) to 
investigate their in vitro deposition. Results showed that the fine particle fraction is 
approximately 15% and the mass mean aerodynamic diameter is 3.9 m (54). The higher 
experimental mass mean aerodynamic diameter of the microparticles, compared to the 
theoretical one, could be explained by the incomplete powder deaggregation in the dry 
powder inhaler (67). Besides, chitosan microspheres display low toxicity, a controlled 
release pattern and improved systemic delivery and, hence, show a particular promise for 
systemic delivery to the lungs (54). 
The spray-drying technique was also used to produce microspheres loaded with 
drugs for local effects, such as the glucocorticoid steroids betamethasone (68,69) and 
beclometasone dipropionate (70), and the 2-adrenergic agonists salbutamol (71) and 
terbutaline sulphate (70), used in the treatment of bronchial asthma. Bethametasone-loaded 
chitosan microspheres (encapsulation efficiencies up to 95%) containing type-A gelatine 
and ethylene oxide-propylene oxide block copolymer (Pluronic F68) as modifiers, were 
spherical and smooth and had a size distribution of 1-5 m and a density of < 0.4 g/cm3 
(68,69). By properly choosing excipient type and concentration, a high degree of control 
was achieved over their physical properties (shape, size and surface morphology) and in 
vitro drug release. Microspheres had good stability, high entrapment efficiency and a 
positive surface charge (+37.5 mV) (68,69). As it was already mentioned in section 4, 
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betamethasone-loaded chitosan microspheres induced pro-inflammatory responses in rat 
lung tissues in a dose-dependent manner, which demonstrated to be mild as compared to 
other materials proposed for lung delivery, such as lipopolysaccharides (51) or 
poly(lactide-co-glycolide) (PLGA), this later being one of the most commonly studied 
excipients for controlled release to the lungs (54).  
Chitosan microspheres containing -cyclodextrin (chitosan/-cyclodextrin 
microspheres) and loaded with theophylline (drug entrapment between 13 and 36%, yields 
and encapsulation efficiencies higher than 45%), have demonstrated to constitute a 
biocompatible and safe sustained release carrier for pulmonary delivery. The microspheres 
are spherical, with smooth or wrinkled surfaces, and hold low tap densities (0.34 - 0.48 
g/cm3) and appropriate aerodynamic diameters (2.20 - 3.04 m) for pulmonary delivery. 
Besides, they have the ability to provide a sustained release of the drug, releasing 72% in 
12 hours (53,72). 
Chitosan was used as an emulsion stabilizer in the preparation of the PLGA, poly-ε-
caprolactone (PCL) and combined PLGA + PCL microspheres. The polysaccharide not 
only imparts a positive charge to the surface of the microspheres, which is an important 
characteristic for mucosal absorption and translocation of particles through the mucosa, but 
is also able to increase their loading efficiency. Combined PLGA+PCL microspheres 
display substantially altered release kinetics, which may be useful in the delivery of the 
antitubercular drug rifampicin and other agents that may benefit from sustained and 
controlled delivery profiles (73). It is worthy to mention that several advantages have been 
proposed for administering antitubercular drugs in particulate lung carriers, including a 
reduction in the dose and frequency of administration, increasing patient compliance, as 
well as drug targeting to macrophages that harbor Mycobacterium tuberculosis. This 
enables to address the disease locally, thus allowing the attainment of high drug 
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concentrations and controlled release at the site of action, and reducing side effects usually 
accompanied with their systemic administration.  
With the same purpose, rifampicin-loaded PLGA, chitosan and PLGA/chitosan 
microparticles were prepared using the technique of emulsion or precipitation, being 
compared for their stability during nebulisation. It was shown that the proper combination 
of both polymers enabled the formation of very stable PLGA/chitosan microspheres with 
high drug loading capacity and nebulisation ability. Moreover, encapsulation efficiency, 
percentage of drug collected in nebulised microparticles and nebulisation efficiencies were 
found to increase proportionally with the chitosan content. Cytotoxicity assays performed 
with these carriers, demonstrated lower cytotoxicity towards alveolar epithelial cells as 
compared to plain PLGA microspheres, and mucoadhesive properties similar to those 
found for chitosan microspheres were reported (74,75). Results generated by the referred 
study should be considered with particular attention in the design of colloidal formulations 
of other drugs, especially if increased mucoadhesion is desired. In fact, if not of particular 
interest for rifampicin-loaded microspheres, which are aimed for macrophage uptake, 
enhancement of the mucoadhesiveness of particles intended for delivery to the lungs 
through surface modification, may be required in other different cases. In line with this, the 
fact that PLGA/chitosan microspheres, which display the best stability profile during 
nebulization, have a positive surface charge and very good mucoadhesive properties, is 
indeed a considerable advantage for many therapeutic applications.  
 
5.3. Chitosan-based nanoparticles 
The administration of nanoparticles through the lung route presents a severe 
challenge owing to their small dimensions. In this sense, and taking into account previous 
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considerations made on particles/droplets size for lung delivery (see introduction), 
nanoparticles have to be administered as droplets or powdered particles incorporating a 
number of nanostructures. In both cases, apart from the nanoparticle development itself, 
there is a need to endow efforts as well on administration technologies and/or devices and 
all the stability/compatibility issues derived from that process. Maybe this is a valuable 
justification for the fact that there is a much fewer number of chitosan-based nanoparticles 
proposed for pulmonary delivery compared to microparticles. 
We have reported the preparation of chitosan / tripolyphosphate (CS/TPP) 
nanoparticles via an extremely mild and rapid ionotropic gelation procedure with the 
counter-ion sodium TPP (76,77). These nanoparticles showed an excellent capacity for 
protein entrapment and an improvement of peptide absorption across mucosal surfaces, 
such as the nasal and ocular (19-21). Later on, the composition and structure of these 
nanopacrticles was adapted for different applications and administration routes. Hence, a 
new generation of safe hybrid nanoparticles consisting of chitosan and either anionic 
hyaluronic acid or cyclodextrin derivatives were developed intended for  pulmonary and 
nasal delivery of peptides (78,79) and gene therapy (80). TEM microphotographs of the 
chitosan nanoparticles formulations are shown in Figure 2. 
The rational behind the design of the chitosan/-cyclodextrin (sulfobutylether--
cyclodextrin and carboximethyl--cyclodextrin) nanocarriers was to combine the 
advantageous behaviour of chitosan nanoparticles with the excellent biopharmaceutical 
properties of cyclodextrins. Indeed, cyclodextrins are very well known in the 
pharmaceutical field because of their ability to protect drugs from physical, chemical and 
enzymatic degradation, and to enhance membrane permeability (81,82). Besides, they have 
been conjugated with polycationic polymers (polyamidine, polyethylenimine) and 
dendrimers, to form polyplexes, which elicit an increased transfection efficiency and 
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stability against enzymatic degradation with low in vitro and in vivo toxicity (82-85). The 
mechanism of formation of the chitosan/-cyclodextrin nanoparticles nanosystems 
combines the electrostatic interaction between chitosan and cyclodextrins, which are 
oppositely charged, with the ability of chitosan to undergo a liquid–gel transition due to its 
ionic interaction with TPP.  
Bearing all this information in mind, we hypothesised that the incorporation of 
cyclodextrins to the already effective chitosan-based gene delivery-nanocarriers could 
positively contribute to promote cellular uptake and decrease the cytotoxicity of the 
systems. In fact, in a Calu-3 cell culture model, chitosan/cyclodextrin nanoparticles were 
shown to cause a reversible reduction in the transepithelial resistance of the cell 
monolayer, thus increasing the membrane permeability (79) and to have the ability to enter 
epithelial cells and promote gene expression (80). These nanoparticles presented an 
adequate size range (100–200 nm, depending on chitosan molecular weight, MW), a 
positive surface charge (+22 to +35 mV) and very high DNA association efficiency 
(>90%). The ability of the nanoparticles to entrap pDNA was in agreement with the 
previous results obtained for other chitosan-based nanometric systems, and it can be easily 
explained by the high affinity of chitosan for the DNA (86, 87). Indeed, it is known that the 
strong electrostatic interaction exists between the phosphate groups of DNA and the amino 
groups of CS, as well as hydrophobic and hydrogen bonds (88).  
The transfection efficiency of the different formulations, measured by the 
concentration of secreted gene product (SEAP) (plasmid DNA model that encodes the 
expression of secreted alkaline phosphatase) indicated that all the nanoparticles were able 
to elicit a significantly higher response than the naked DNA (control), the transfection 
efficiency being more important for low MW chitosan nanoparticles than for those 
composed of medium MW chitosan (Figure 3). Furthermore, these nanoparticles exhibited 
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a low toxicity. Considering all these observations, these nanocarriers represent a promising 
approach for gene therapy at the level of mucosal surfaces and, in particular, the 
respiratory mucosa (79, 80). 
A mucoadhesive nanocarrier made from chitosan and hyaluronic acid and loaded 
with the macromolecular drug heparin was produced which was suitable for pulmonary 
delivery and use in antiasthmatic therapy (78). Hyaluronic acid is a naturally occurring 
hydrogel based on a linear polysaccharide comprised of repeating units of D-glucuronic 
acid and N-acetyl-D-glucosamine, linked by β-1,4 and β-1,3 glycosidic bonds. 
Applications using hyaluronic acid for pulmonary controlled drug delivery are reported in 
literature (89). Chitosan and mixtures of hyaluronic acid with two unfractionated or low-
molecular-weight heparins were combined to form nanoparticles by the ionotropic gelation 
technique. The resulting heparin-loaded nanoparticles were between 152 and 217 nm in 
size, their zeta potential ranged from +28.1 to +34.6 mV, and association efficiency was up 
to 70%. The nanosystems were stable in phosphate buffered saline pH 7.4 for at least 
24 hours and were effectively internalized by rat mast cells. Ex vivo experiments aimed at 
evaluating the capacity of heparin to prevent histamine release in rat mast cells indicated 
that the free or encapsulated drug exhibited the same dose–response behaviour (78). 
Using the same technique of ionic gelation, Huang et al. produced FITC-labelled 
CS/TPP nanoparticles of 200 nm with a positive zeta potential of approximately 36 mV, 
and investigated their uptake by the A549 cells. Results demonstrated that the 
nanoparticles uptake was concentration- and temperature-dependent, increasing with 
higher concentration and decreasing with lower temperatures (inhibition at 4 ºC compared 
to 37 ºC). Uptake of chitosan nanoparticles was 1.8 fold higher than that of chitosan 
solution (68). In a more recent study, the same authors demonstrated that chitosan MW and 
deacetylation degree (DD) affected the uptake efficiency by modulating the particles zeta 
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potential. In this respect, it was reported that the binding affinity and the uptake capacity 
decreased when decreasing chitosan MW and DD, the best performance being shown by 
the nanoparticles produced with chitosan 213 KDa and 88% deacetylated. Moreover, the 
authors found that chitosan solution and nanoparticles exhibit similar cytotoxicity (50). 
 Following a different approach, Yamamoto et al. produced PLGA nanospheres by 
nanoprecipitation (emulsion solvent diffusion) and included chitosan afterwards as a 
surface modifier by simply incubating the preformed nanospheres in a solution of the 
polymer. The developed nanoparticles, modified with chitosan, presented a size of 
approximately 650 nm and efficiently encapsulated elcatonin. Nanoparticles were assessed 
for their aerosolisation pattern using a nebuliser, resulting in aerosol droplets with a 
geometrical diameter of 6.5 μm, which led to a respirable fraction of 51%. The in vivo 
performance of these nanospheres was also evaluated upon nebulisation to guinea pigs. 
They evidenced a slower elimination rate from the lung than the unmodified particles and 
the presence of chitosan resulted in a prolonged and stronger hypocalcaemic effect of 
elcatonin, which was attributed to the mucoadhesive properties of chitosan, as well as to its 
ability to transiently open tight junctions (22). 
It has already been established that spray drying constitutes a very valuable 
technique for producing dry powders adequate for pulmonary delivery of drugs (63,64). 
Therefore, we believed that the severe limitation of the pulmonary administration of 
chitosan nanoparticles due to their small size could be circumvented by using a spray-
drying process to encapsulate them in microspheres, thus obtaining a dry powder which 
possesses adequate properties to reach the deep lung. In fact, protein-loaded chitosan 
nanoparticles were microencapsulated using the carbohydrate mannitol (90), which is a 
typical aerosol excipient approved by the Food and Drug Administration (FDA) and other 
regulatory organisms for inhalation purposes (67). SEM microphotographs shown in 
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Figure 4 reveal that the obtained microspheres are mostly spherical and possess appropriate 
aerodynamic properties for pulmonary delivery (aerodynamic diameters between 2 and 3 
m, apparent density lower than 0.45 g/cm3). Moreover, their morphology was strongly 
affected by the nanoparticles content. Chitosan nanoparticles show a good protein loading 
capacity (65–80%), providing the release of 75–80% insulin within 15 min, and can be 
easily recovered from microspheres after contact with an aqueous medium with no 
significant changes in their size and zeta potential values. 
Based on the previous considerations and acquired knowledge about the 
chitosan/TPP nanoparticles benefits when administered by other routes, we hypothesized 
that these microspheres, with an aerodynamic diameter between 1 and 5 µm, once inhaled, 
are expected to reach and deposit in the deep lung where the carrier carbohydrate will 
dissolve, delivering the nanoparticles, which will then promote the absorption of the 
associated therapeutic macromolecule. Importantly, mannitol was shown to act simply as 
inert carrier of the nanoparticles to the lung, as it completely dissolves upon in vitro 
incubation with an aqueous medium, as that found in the lung environment, releasing the 
nanoparticles without any significant changes in their physicochemical characteristics (300 
nm and a positive zeta potential of + 34 mV) or the protein release profile (90).  
Accurate analysis of the surface and inner structure of the system using confocal 
microscopy, X-ray photoelectron spectroscopy and time-of-flight secondary ion mass 
spectrometry, revealed an even distribution of the nanoparticles through the whole 
microparticle (91). These chitosan nanoparticle-loaded microspheres were further 
demonstrated to be biocompatible with two different pulmonary cell lines of human origin, 
Calu-3 and A549 cells, which are representative of the bronchial and alveolar epithelium, 
respectively (Figure 5). In that study, nanoparticle concentration corresponding to amounts 
of chitosan as high as 1 mg/mL did not induce overt cell toxicity for up to 48 hours. 
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Furthermore, as mentioned in section 4, uptake studies suggested that nanoparticles were 
not internalised by the cells, but evidenced adhesion to the cell membranes (41). 
In vivo studies (microencapsulated insulin-loaded chitosan nanoparticles containing 
20% insulin and 80% mannitol) further indicated the suitability of the developed system. 
Upon intratracheal administration to anesthetised rats (16.7 IU insulin/kg) using a 
Harvard® ventilator that allows to simulate the physiological breathing mode of rats, the 
hypoglycemic response was compared with that of an insulin solution of the same doses. 
Curves depicted in Figure 6 demonstrate that microencapsulated insulin-loaded chitosan 
nanoparticles induce a strong and prolonged (up to 240 min.) hypoglycemic effect, and that 
the glucose level decreases to a greater extent as compared with that of control insulin 
(70% against 40% of the basal blood glucose at 60 min. post-administration). The novel 
dry powder carrier incorporating nanoparticles into a micron-scale structure has the 
advantage, when compared to liquid formulations, of improved stability and easiness of 
administration. In definitive, it allows overcoming the issues of storage and pulmonary 
administration of nanoparticles, and constitutes a very promising carrier for lung delivery 
of therapeutic proteins (92). 
Encouraged by these results and given the favourable properties already 
commented of the hybrid nanocarriers (78-80), we are developing similar carriers 
composed of mannitol microspheres encapsulating chitosan-hyaluronic or chitosan-
cyclodextrin nanoparticles. Nanoparticles and microspheres were produced using the same 
methods as before, ionic gelation and spray-drying, respectively. Both types of 
nanoparticles were spherical and compact structures (Figure 4) and displayed a size in the 
nanometric range and a positive zeta potential.  
 
6. Main remarks 
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According to the aforementioned comments, it is clear that chitosan and its 
derivatives represent excellent materials to produce lung delivery carriers. Techniques such 
as ionotropic gelation and spray-drying are very useful in the preparation of chitosan 
nanoparticles and microspheres for this purpose. Special attention should be paid to the 
encouraging results related to the absorption of peptides and proteins using 
microencapsulated nanoparticles. However, many challenges have to be faced from now 
on biocompatibility and chitosan carriers will only be successfully administered through 
the lung when they have such properties that enable them to overcome the distinct barriers, 
including difficult accessibility, aerodynamic specificities and the mucociliary clearance. 
Whilst encouraging results may be achieved in cell culture and animal models, promising 
agents such as chitosan needs to be proven in clinical trial. 
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Table I – Examples of chitosan-based formulations and molecules under investigation.  
 
 
Chitosan formulation Molecule Ref. 
  Chitosan solutions   
     Chitosan, 60% N-trimethyl chitosan (TMC60) Octreotide (48) 
     Chitosan oligomer (hexamer, 985Da) Interferon- (49) 
  Chitosan microspheres 
  
     Chitosan    Insulin 
  Fluorescein isothiocyanate-labelled 
  bovine serum albumin (FITC-BSA) 
(5) 
(5) 
     Chitosan    Bethametasone 
  Beclometasone dipropionate 
  Salbutamol 
  Terbutaline sulphate 
(68,69) 
(70) 
(71) 
(70) 
     Chitosan/-cyclodextrin    Theophylline (53,72) 
     Chitosan, chitosan/PLGA, chitosan /PCL   Rifampicin (73) 
  Chitosan nanoparticles 
  
     Chitosan/tripolyphosphate   Insulin  
     Chitosan/hyaluronic acid/tripolyphosphate   Heparin (78) 
     Chitosan/--cyclodextrin/tripolyphosphate   Plasmid DNA model (80) 
     Chitosan-coated PLGA nanoparticles   Elcatonin (22) 
  Microencapsulated chitosan nanoparticles   Insulin (90) 
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FIGURE CAPTIONS 
Figure 1 – Chemical structure of chitosan. 
Figure 2 – TEM microphotographs of chitosan nanoparticles produced with different 
compositions: (a) chitosan/tripolyphosphate, (b) chitosan/hyaluronic acid/ tripolyphosphate 
and (c) chitosan/carboxymethyl--cyclodextrin/tripolyphosphate nanoparticles. 
Figure 3 - Secreted alkaline phosphatase (SEAP) concentration in the Calu-3 cell culture 
model after transfection with two different nanoparticle formulations: () 
chitosan/sulfobutylether--cyclodextrin nanoparticles and () chitosan/carboximethyl--
cyclodextrin/tripolyphosphate nanoparticles encapsulating pDNA; () control naked 
pDNA (means ± SD, n = 5) Reprinted from (80) (Eur. J. Pharm. Biopharm., 71, Teijeiro-
Osorio et al., Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway 
epithelium in vitro, 257-263, 2009) with permission from Elsevier. 
Figure 4 - SEM microphotographs of mannitol microspheres containing: (a) chitosan / 
tripolyphosphate nanoparticles; (b) chitosan/hyaluronic acid / tripolyphosphate 
nanoparticles and (c) chitosan  / carboxy methyl-β-cyclodextrin nanoparticles. 
Figure 5 – A549 cell viability measured by MTT cytotoxicity assay after 24h exposure to 
increasing concentrations of the () nanoparticle suspension and nanoparticle-containing 
mannitol microspheres with nanoparticle:mannitol ratios of () 90/10; (■) 80/20 and (▲) 
60/40. Data represent mean ± S.E.M. (n = 3 experiments, six replicates per experiment at 
each test concentration) Adapted from (41) (Eur. J. Pharm. Sci., 31, Grenha et al., 
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Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro, 73-84, 
2007) with permission from Elsevier. 
Figure 6 - Hypoglycemic effect following intratracheal administration to rats of () 
microencapsulated insulin-loaded chitosan nanoparticles; () control insulin solution in 
PBS pH 7.4; and () control microencapsulated unloaded chitosan nanoparticles (insulin 
doses = 16.7 U/Kg; n > 3) Adapted from (92) (PO2-22 - EUCHIS 2009, Al-Qadi et al., 
Chitosan nanopaticle-based inhalable dry-powders for protein lung delivery, 2009). 
  47 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
  48 
 
 
 
 
 
 
Figure 2 
a 
b 
c 
  49 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
-0,02
0
0,02
0,04
0,06
0,08
0,1
0,12
0,14
0,16
0 1 2 3 4 5 6
Time  (days)
S
E
A
P
 c
on
ce
nt
ra
tio
n 
(u
g/
m
L)
  50 
 
 
 
 
 
 
 
Figure 4 
b 
c 
a 
  51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 
0
20
40
60
80
100
120
140
160
0,0001 0,001 0,01 0,1 1 10
log NP Conc. (mg/mL)
C
el
l v
ia
bi
lit
y 
(%
)
  52 
 
 
 
 
 
 
 
 
 
Figure 6 
 
 
